Latest KFF Health News Stories
KHN On Call: How Retooled Health Law Might Treat Those With A History Of Illness
People with preexisting conditions will still be able to buy coverage under the GOP plan, but it’s not clear there will be plans anyone can afford.
Five Ways The GOP Health Bill Would Reverse Course From The ACA
From Medicaid funding to paying for over-the-counter drugs, the legislation offered by House Republicans offers a far different pathway to coverage than Obamacare.
Proyecto republicano elimina el mandato individual y gran parte de la expansión del Medicaid
Los republicanos dieron a conocer el plan de salud con el que buscan reemplazar gran parte del Obamacare. Qué disposiciones se conservarían y cuáles podrían desaparecer por completo.
Three Key Senators Ask GAO To Investigate Possible Abuses Of The Orphan Drug Act
Amid an uproar over high drug prices, three GOP senators are asking the Government Accountability Office to investigate whether the Orphan Drug Act is being abused.
House GOP Health Bill Jettisons Insurance Mandate, Much Of Medicaid Expansion
After intense negotiations among party factions, Republican leaders unveil legislation that committees will mark up this week.
With ‘Trumpcare’ On Horizon, Voters Go Wobbly On Repeal
The prospect of repealing the Affordable Care Act – with no replacement ready – finds many having second thoughts.
Advocates Of Flat-Fee Primary Care See Opening In GOP’s Market-Driven Approach
In direct primary care, a monthly fee covers routine care, limiting insurers’ role. But does it really provide better value?
Drowning In A ‘High-Risk Insurance Pool’ — At $18,000 A Year
Minnesota had one of the most successful high-risk insurance pools in the country, and GOP leaders are eyeing this special insurance for sick people as an Obamacare replacement. But analysts say costs were high and many people in need were left out.
KHN On Call: When Is ACA Repeal For Real?
Julie Rovner of Kaiser Health News answers NPR listener questions like: Has Obamacare been repealed? No. Not yet.
Congressman’s Ties To Foreign Biotech Draw Criticism
Rep. Chris Collins’ enthusiastic investments in Australian biotech company Innate Immunotherapeutics preceded share purchases by the Buffalo Republican’s family members, associates and political donors — raising questions from Washington, D.C., to Sydney.
Right-To-Die Fight Hits National Stage
A Republican-led effort to overturn D.C.’s aid-in-dying law may catalyze a broader effort to ban the practice nationally.
Docs Bill Medicare For End-Of-Life Advice As ‘Death Panel’ Fears Reemerge
The federal program paid $16 million in the first six months of 2016 to counsel 223,000 patients about treatment preferences in their last days.
Influence Of GOP Doctors Caucus Grows As Congress Looks To Replace Health Law
As conservative physicians rise to more powerful positions in government, some question whether they speak for the nation’s doctors.
Medicaid: todo lo que necesita saber sobre el financiamiento “en bloque”
El presidente Donald Trump propone cambiar drásticamente el vínculo entre el gobierno federal y los estados, a la hora de repartir el dinero para gerenciar el programa que ayuda a las familias de bajos ingresos a tener seguro de salud.
Grassley Launches Inquiry Into Orphan Drugs After KHN Investigation
Citing a Kaiser Health News investigation, Senate Judiciary Committee Chairman Chuck Grassley vows to examine the orphan drug program and possible fixes.
HHS Pick Price Made ‘Brazen’ Stock Trades While His Committee Was Under Scrutiny
With federal investigators bearing down on his committee, Rep. Tom Price, R-Ga., who is line to be secretary of the Department of Health and Human Services, showed little restraint in investing in health companies.
A Guide To Budget Reconciliation: The Byzantine Rules For Disassembling The Health Law
Republicans, who don’t have the votes to repeal the ACA directly, are hoping to use this strict budget strategy that requires only a majority vote to strip the health law of provisions they oppose.
Democrats Say Cabinet Choice Tom Price ‘Misled’ The Public. Here’s What We Know.
Concerns over U.S. Rep. Tom Price’s answers about stock trades led Senate Democrats to boycott a committee vote that would have moved his nomination to the Senate floor.
Por qué es tan difícil hallar una cura para el Alzheimer
A pesar de una tasa de fracaso de 99%, científicos que investigan el Alzheimer están avanzando con cientos de experimentos -y un gran impulso en dinero federal- para tratar de revertir una enfermedad mortal que los ha desconcertado por décadas.
Trying To Solve The Alzheimer’s Puzzle
Alzheimer’s researchers hold onto hope after another promising trial ends in disappointment.
